Switch theme
Sign up to access all valuation multiples
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics.
2008
11.0K+
LTM Revenue $1.9B
LTM EBITDA $283M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
RadNet has a last 12-month revenue (LTM) of $1.9B and a last 12-month EBITDA of $283M.
In the most recent fiscal year, RadNet achieved revenue of $1.8B and an EBITDA of $323M.
RadNet expects next 12-month revenue of XXX and NTM EBITDA of XXX
See RadNet valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9B | XXX | $1.8B | XXX | XXX | XXX |
| Gross Profit | $243M | XXX | $249M | XXX | XXX | XXX |
| Gross Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA | $283M | XXX | $323M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $111M | XXX | $111M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $4.6M | XXX | $2.8M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | 0% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $276M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 3, 2025, RadNet's stock price is $56.
RadNet has current market cap of $4.2B, and EV of $5.2B.
See RadNet trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.2B | $4.2B | XXX | XXX | XXX | XXX | $0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 3, 2025, RadNet has market cap of $4.2B and EV of $5.2B.
RadNet's trades at 2.8x EV/Revenue multiple, and 16.1x EV/EBITDA.
Equity research analysts estimate RadNet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
RadNet has a P/E ratio of 909.6x.
See valuation multiples for RadNet and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV (current) | $5.2B | XXX | $5.2B | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 18.4x | XXX | 16.1x | XXX | XXX | XXX |
| EV/EBIT | 46.7x | XXX | 46.8x | XXX | XXX | XXX |
| EV/Gross Profit | 21.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 909.6x | XXX | 1495.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 4028.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRadNet's last 12 month revenue growth is 8%
RadNet's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $13K for the same period.
RadNet's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
RadNet's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for RadNet and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $13K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RadNet acquired XXX companies to date.
Last acquisition by RadNet was XXXXXXXX, XXXXX XXXXX XXXXXX . RadNet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was RadNet founded? | RadNet was founded in 2008. |
| Where is RadNet headquartered? | RadNet is headquartered in United States of America. |
| How many employees does RadNet have? | As of today, RadNet has 11.0K+ employees. |
| Who is the CEO of RadNet? | RadNet's CEO is Dr. Howard G. Berger,M.D.. |
| Is RadNet publicy listed? | Yes, RadNet is a public company listed on NAS. |
| What is the stock symbol of RadNet? | RadNet trades under RDNT ticker. |
| When did RadNet go public? | RadNet went public in 1994. |
| Who are competitors of RadNet? | Similar companies to RadNet include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of RadNet? | RadNet's current market cap is $4.2B |
| What is the current revenue of RadNet? | RadNet's last 12 months revenue is $1.9B. |
| What is the current revenue growth of RadNet? | RadNet revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of RadNet? | Current revenue multiple of RadNet is 2.7x. |
| Is RadNet profitable? | Yes, RadNet is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of RadNet? | RadNet's last 12 months EBITDA is $283M. |
| What is RadNet's EBITDA margin? | RadNet's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of RadNet? | Current EBITDA multiple of RadNet is 18.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
